dc.creator | Stacchiotti, S. | es |
dc.creator | Miah, A. B. | es |
dc.creator | Frezza, A. M. | es |
dc.creator | Messiou, C. | es |
dc.creator | Morosi, C. | es |
dc.creator | Caraceni, A. | es |
dc.creator | Álava Casado, Enrique de | es |
dc.creator | Gronchi, A. | es |
dc.date.accessioned | 2022-11-14T15:58:13Z | |
dc.date.available | 2022-11-14T15:58:13Z | |
dc.date.issued | 2021 | |
dc.identifier.citation | Stacchiotti, S., Miah, A.B., Frezza, A.M., Messiou, C., Morosi, C., Caraceni, A.,...,Gronchi, A. (2021). Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts. ESMO open, 6 (3), 100170. https://doi.org/10.1016/j.esmoop.2021.100170. | |
dc.identifier.issn | 2059-7029 | es |
dc.identifier.uri | https://hdl.handle.net/11441/139407 | |
dc.description.abstract | Epithelioid hemangioendothelioma (EHE) is an ultra-rare, translocated, vascular sarcoma. EHE clinical behavior is
variable, ranging from that of a low-grade malignancy to that of a high-grade sarcoma and it is marked by a high
propensity for systemic involvement. No active systemic agents are currently approved specifically for EHE, which is
typically refractory to the antitumor drugs used in sarcomas. The degree of uncertainty in selecting the most
appropriate therapy for EHE patients and the lack of guidelines on the clinical management of the disease make the
adoption of new treatments inconsistent across the world, resulting in suboptimal outcomes for many EHE patients.
To address the shortcoming, a global consensus meeting was organized in December 2020 under the umbrella of
the European Society for Medical Oncology (ESMO) involving >80 experts from several disciplines from Europe,
North America and Asia, together with a patient representative from the EHE Group, a global, disease-specific
patient advocacy group, and Sarcoma Patient EuroNet (SPAEN). The meeting was aimed at defining, by consensus,
evidence-based best practices for the optimal approach to primary and metastatic EHE. The consensus achieved
during that meeting is the subject of the present publication. | es |
dc.format | application/pdf | es |
dc.format.extent | 14 p. | es |
dc.language.iso | eng | es |
dc.publisher | Elsevier | es |
dc.relation.ispartof | ESMO open, 6 (3), 100170. | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Sarcoma | es |
dc.subject | Epithelioid hemangioendothelioma | es |
dc.subject | Diagnosis | es |
dc.subject | Treatment | es |
dc.subject | Management | es |
dc.subject | Guidelines | es |
dc.title | Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts | es |
dc.type | info:eu-repo/semantics/article | es |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Citología e Histología Normal y Patológica | es |
dc.relation.publisherversion | https://www.sciencedirect.com/science/article/pii/S2059702921001307?via%3Dihub | es |
dc.identifier.doi | 10.1016/j.esmoop.2021.100170 | es |
dc.journaltitle | ESMO open | es |
dc.publication.volumen | 6 | es |
dc.publication.issue | 3 | es |
dc.publication.initialPage | 100170 | es |